exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087607 RNA Name: hsa-miR-106b-5p RNA Type: miRNA Chromosome: chr7 Starnd: - Coordinate: Start Site(bp): 100094043 End Site(bp): 100094063 External Links: hsa-miR-106b-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand MTHFR chr1 11785723 11806455 - MYCN chr2 15940550 15947007 + PXDN chr2 1631887 1744852 - C9orf40 chr9 74946583 74952912 - PPARD chr6 35342558 35428191 + AFF4 chr5 132875395 132963634 - WDR37 chr10 1049538 1132384 + RAB31 chr18 9708275 9862551 + SCAMP2 chr15 74843730 74873365 - OCRL chrX 129539849 129592561 + ZSCAN26 chr6 28267010 28278224 + ZNF566 chr19 36445119 36489902 - APP chr21 25880550 26171128 - AMPD2 chr1 109616104 109632053 + FOXK1 chr7 4682295 4771442 + ZDHHC12 chr9 128720870 128724127 - KLHL28 chr14 44924319 45042322 - ZNF468 chr19 52838010 52857649 - RACGAP1 chr12 49976923 50033136 - STRN3 chr14 30893799 31026401 - USP24 chr1 55066359 55215364 - WDR36 chr5 111091716 111130502 + LONP2 chr16 48244300 48363122 + LDLRAD3 chr11 35943981 36232136 + PBXIP1 chr1 154944076 154956123 - WASF3 chr13 26557683 26688948 + RPP14 chr3 58306247 58324695 + SLAIN2 chr4 48341529 48426201 + PXYLP1 chr3 141228726 141367753 + MTERF4 chr2 241072169 241102332 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000494 chr13 76134888 76143643 + hsa_circ_0000018 chr1 15860731 15863309 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC015871.3 chr15 79920195 79922455 - AC021078.1 chr5 149494314 149504670 - AC021092.1 chr19 44103007 44113183 - AC024940.6 chr12 31280422 31280895 - AC084082.1 chr8 66112667 66126632 + AC087477.2 chr15 96354237 96405235 + AC243964.3 chr19 44631573 44725217 - AL031428.1 chr1 23020147 23088058 - AL137782.1 chr13 75549773 75807120 + AL158206.1 chr9 19453209 19455173 + AL161772.1 chr13 20699307 20703718 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - CKMT2-AS1 chr5 81201341 81301565 - EPB41L4A-AS1 chr5 112160526 112164818 + ERICD chr8 140636281 140638283 + FGD5-AS1 chr3 14920347 14948424 - H19 chr11 1995176 2001470 - HAGLR chr2 176164051 176188958 - HOTAIR chr12 53962308 53974956 - MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.